Accessibility Menu
XBiotech logo

XBiotech

(NASDAQ) XBIT

Current Price$2.30
Market Cap$69.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-88%
5 Year-86%
1 Year-17%
1 Month-3%

XBiotech Financials at a Glance

Market Cap

$69.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$40.16M

EPS (TTM)

-$1.32

P/E Ratio

-1.74

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$2.30

Volume

5

Open

$2.31

Previous Close

$2.29

Daily Range

$2.28 - $2.31

52-Week Range

$2.09 - $3.61

Estimated Earnings Date

May 12, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About XBiotech

Industry

Biotechnology

Employees

87

CEO

Sushma Shivaswamy, PhD

Headquarters

Austin, TX 78744, US

XBIT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-26.10%

Return on Capital

-39.68%

Return on Assets

-28.72%

Earnings Yield

-57.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$69.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

30.49M

Volume

5

Avg. Volume

30.29K

Financials (TTM)

Gross Profit

-$332.00K

Operating Income

-$48.41M

EBITDA

-$38.33M

Operating Cash Flow

-$42.17M

Capital Expenditure

-$195.00K

Free Cash Flow

-$42.36M

Cash & ST Invst.

$115.46M

Total Debt

$0.00

XBiotech Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$332.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$69.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$758.88K

N/A

Employees

92

N/A

Net Income

-$5.51M

+49.4%

EBITDA

-$5.12M

+50.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$115.46M

-25.9%

Total Debt

$0.00

N/A

Accounts Receivable

$302.00K

-52.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-28.72%

N/A

Return on Invested Capital

-35.38%

N/A

Free Cash Flow

-$8.97M

-31.6%

Operating Cash Flow

-$8.97M

-33.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GANXGain Therapeutics, Inc.
$1.68+0.00%
ACRVAcrivon Therapeutics, Inc. Common Stock
$1.92-9.86%
ACETAdicet Bio, Inc.
$8.68-1.70%
TCRXTScan Therapeutics, Inc.
$0.92-0.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$31.27-0.16%
NOKNokia
$11.25-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$38.94+0.01%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.44-0.01%

Questions About XBIT

What is the current price of XBiotech?

XBiotech is trading at $2.29 per share.

What is the 52-week range for XBiotech?

Over the past 52 weeks, XBiotech has traded between $2.09 and $3.61.

How much debt does XBiotech have?

As of the most recent reporting period, XBiotech reported total debt of $0.00.

How much cash does XBiotech have on hand?

XBiotech reported $115.46M in cash and cash equivalents in its most recent financial results.

What is XBiotech’s dividend yield?

XBiotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.